SCHEMBL16185141

SCHEMBL16185141

CCOc1cc(-c2ccc(F)cc2)cc2c(NC)nc(-c3cccnn3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 3/20 0.42
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ EGFR P00533 4/20 0.35
▸ GRM5 P41594 3/20 0.34
▸ ERBB2 P04626 2/20 0.34
▸ S1PR1 P21453 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ CASP6 P55212 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185165 0.94 GRM5 (0.36) CHRNA7LMNAMAPTEGFRGRM5
SCHEMBL16185136 0.92 GRM5 (0.44) CHRNA7LMNAMAPTEGFRGRM5
SCHEMBL16185155 0.90 CHRNA7 (0.37) CHRNA7LMNAMAPTEGFRGRM5
SCHEMBL16185148 0.90 CHRNA7 (0.37) CHRNA7LMNAMAPTEGFRGRM5
SCHEMBL14474196 0.89 KDM4E (0.39) LMNAMAPTKDM4EALDH1A1CYP3A4
SCHEMBL14474198 0.88 S1PR1 (0.46) CHRNA7LMNAGRM5S1PR1KDM4E
SCHEMBL14475257 0.88 GRM5 (0.35) CHRNA7LMNAEGFRGRM5S1PR1
SCHEMBL14474675 0.86 KLKB1 (0.34) CHRNA7LMNAEGFRGRM5S1PR1
SCHEMBL14474192 0.86 CHRNA7 (0.43) CHRNA7LMNAMAPTEGFRGRM5
SCHEMBL16184853 0.83 HSD17B10 (0.47) CHRNA7MAPTGRM5S1PR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CHRNA7 349/4885LMNA 4832/4885MAPT 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback